Unknown

Dataset Information

0

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.


ABSTRACT: Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC).82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by the Kaplan-Meier method.Median PFS was 4.0 months (95% CI 2.311-5.689). Median OS was 11.0 months (95% CI 8.537-13.463) in this cohort. Median PFS for first and second/third line were 7.0 months (95% CI 2.151-11.8) and 3.0 months (95% CI 1.042-4.958), respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305-15.695) and 10.0 months (95% CI 7.295-12.70), respectively. In patients with EGFR mutation (n = 19), icotinib significantly reduced the risk of progression (HR 0.36, 95% CI 0.18-0.70, p = 0.003) and death (HR 0.10, 95% CI 0.02-0.42, p = 0.002) compared with those EGFR status unknown (n = 63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%).Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile.

SUBMITTER: Chen X 

PROVIDER: S-EPMC4023939 | BioStudies | 2014-01-01

SECONDARY ACCESSION(S): NCT01646450

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC6943154 | BioStudies
2017-01-01 | S-EPMC5362911 | BioStudies
2020-01-01 | S-EPMC7202306 | BioStudies
2019-01-01 | S-EPMC6614728 | BioStudies
2020-01-01 | S-EPMC7600176 | BioStudies
2018-01-01 | S-EPMC6280988 | BioStudies
2014-01-01 | S-EPMC3922700 | BioStudies
2020-01-01 | S-EPMC6993327 | BioStudies
2019-01-01 | S-EPMC6493697 | BioStudies
2014-01-01 | S-EPMC3887309 | BioStudies